120 related articles for article (PubMed ID: 8014871)
1. Plasma levels of a novel noncyclooxygenase-derived prostanoid (8-isoprostane) correlate with severity of liver injury in experimental alcoholic liver disease.
Nanji AA; Khwaja S; Tahan SR; Sadrzadeh SM
J Pharmacol Exp Ther; 1994 Jun; 269(3):1280-5. PubMed ID: 8014871
[TBL] [Abstract][Full Text] [Related]
2. Increased lipid peroxidation and impaired antioxidant enzyme function is associated with pathological liver injury in experimental alcoholic liver disease in rats fed diets high in corn oil and fish oil.
Polavarapu R; Spitz DR; Sim JE; Follansbee MH; Oberley LW; Rahemtulla A; Nanji AA
Hepatology; 1998 May; 27(5):1317-23. PubMed ID: 9581686
[TBL] [Abstract][Full Text] [Related]
3. Alterations in nuclear ploidy and cell phase distribution of rat liver cells in experimental alcoholic liver disease: relationship to antioxidant enzyme gene expression.
Fogt F; Nanji AA
Toxicol Appl Pharmacol; 1996 Jan; 136(1):87-93. PubMed ID: 8560485
[TBL] [Abstract][Full Text] [Related]
4. Cimetidine prevents alcoholic hepatic injury in the intragastric feeding rat model.
Nanji AA; Zhao S; Khwaja S; Sadrzadeh SM; Waxman DJ
J Pharmacol Exp Ther; 1994 May; 269(2):832-7. PubMed ID: 8182552
[TBL] [Abstract][Full Text] [Related]
5. A voluntary oral ethanol-feeding rat model associated with necroinflammatory liver injury.
Tipoe GL; Liong EC; Casey CA; Donohue TM; Eagon PK; So H; Leung TM; Fogt F; Nanji AA
Alcohol Clin Exp Res; 2008 Apr; 32(4):669-82. PubMed ID: 18341647
[TBL] [Abstract][Full Text] [Related]
6. Alterations in glucose transporter proteins in alcoholic liver disease in the rat.
Nanji AA; Fogt F; Griniuviene B
Am J Pathol; 1995 Feb; 146(2):329-34. PubMed ID: 7856745
[TBL] [Abstract][Full Text] [Related]
7. Role of transforming growth factor-[beta]1 in inhibiting endothelial cell proliferation in experimental alcoholic liver disease.
Nanji AA; Tahan SR; Golding M; Khwaja S; Rahemtulla A; Lalani EN
Am J Pathol; 1996 Mar; 148(3):739-47. PubMed ID: 8774130
[TBL] [Abstract][Full Text] [Related]
8. Dietary saturated fatty acids down-regulate cyclooxygenase-2 and tumor necrosis factor alfa and reverse fibrosis in alcohol-induced liver disease in the rat.
Nanji AA; Zakim D; Rahemtulla A; Daly T; Miao L; Zhao S; Khwaja S; Tahan SR; Dannenberg AJ
Hepatology; 1997 Dec; 26(6):1538-45. PubMed ID: 9397995
[TBL] [Abstract][Full Text] [Related]
9. Association between endothelial cell proliferation and pathologic changes in experimental alcoholic liver disease.
Nanji AA; Tahan SR
Toxicol Appl Pharmacol; 1996 Sep; 140(1):101-7. PubMed ID: 8806875
[TBL] [Abstract][Full Text] [Related]
10. Fatty acid omega- and (omega-1)-hydroxylation in experimental alcoholic liver disease: relationship to different dietary fatty acids.
Amet Y; Adas F; Nanji AA
Alcohol Clin Exp Res; 1998 Oct; 22(7):1493-500. PubMed ID: 9802534
[TBL] [Abstract][Full Text] [Related]
11. Activation of nuclear factor kappa B and cytokine imbalance in experimental alcoholic liver disease in the rat.
Nanji AA; Jokelainen K; Rahemtulla A; Miao L; Fogt F; Matsumoto H; Tahan SR; Su GL
Hepatology; 1999 Oct; 30(4):934-43. PubMed ID: 10498645
[TBL] [Abstract][Full Text] [Related]
12. Medium chain triglycerides and vitamin E reduce the severity of established experimental alcoholic liver disease.
Nanji AA; Yang EK; Fogt F; Sadrzadeh SM; Dannenberg AJ
J Pharmacol Exp Ther; 1996 Jun; 277(3):1694-700. PubMed ID: 8667240
[TBL] [Abstract][Full Text] [Related]
13. The long-acting parenteral iron chelator, hydroxyethyl starch-deferoxamine, fails to protect against alcohol-induced liver injury in rats.
Sadrzadeh SM; Hallaway PE; Nanji AA
J Pharmacol Exp Ther; 1997 Feb; 280(2):1038-42. PubMed ID: 9023321
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol supplementation prevents necrosis and inflammation but enhances fibrosis in alcoholic liver disease in the rat.
Nanji AA; Rahemtulla A; Daly T; Khwaja S; Miao L; Zhao S; Tahan SR
Hepatology; 1997 Jul; 26(1):90-7. PubMed ID: 9214456
[TBL] [Abstract][Full Text] [Related]
15. Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-alpha (PPARalpha)-regulated genes and is ameliorated by PPARalpha activation.
Nanji AA; Dannenberg AJ; Jokelainen K; Bass NM
J Pharmacol Exp Ther; 2004 Jul; 310(1):417-24. PubMed ID: 15016835
[TBL] [Abstract][Full Text] [Related]
16. Severity of liver injury in experimental alcoholic liver disease. Correlation with plasma endotoxin, prostaglandin E2, leukotriene B4, and thromboxane B2.
Nanji AA; Khettry U; Sadrzadeh SM; Yamanaka T
Am J Pathol; 1993 Feb; 142(2):367-73. PubMed ID: 8382006
[TBL] [Abstract][Full Text] [Related]
17. Alterations in thromboxane synthase and thromboxane A2 receptors in experimental alcoholic liver disease.
Nanji AA; Rahemtulla A; Maio L; Khwaja S; Zhao S; Tahan SR; Thomas P
J Pharmacol Exp Ther; 1997 Aug; 282(2):1037-43. PubMed ID: 9262373
[TBL] [Abstract][Full Text] [Related]
18. Intercellular adhesion molecule-1 expression in experimental alcoholic liver disease: relationship to endotoxemia and TNF alpha messenger RNA.
Nanji AA; Griniuviene B; Yacoub LK; Fogt F; Tahan SR
Exp Mol Pathol; 1995 Feb; 62(1):42-51. PubMed ID: 7556590
[TBL] [Abstract][Full Text] [Related]
19. The 21-aminosteroid 16-desmethyl tirilazad mesylate prevents necroinflammatory changes in experimental alcoholic liver disease.
Sadrzadeh SM; Nanji AA
J Pharmacol Exp Ther; 1998 Jan; 284(1):406-12. PubMed ID: 9435204
[TBL] [Abstract][Full Text] [Related]
20. Markedly enhanced cytochrome P450 2E1 induction and lipid peroxidation is associated with severe liver injury in fish oil-ethanol-fed rats.
Nanji AA; Zhao S; Sadrzadeh SM; Dannenberg AJ; Tahan SR; Waxman DJ
Alcohol Clin Exp Res; 1994 Oct; 18(5):1280-5. PubMed ID: 7847620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
